AstraZeneca CEO Pursues Multiple Strands in RNA Drug Quest
This article is for subscribers only.
AstraZeneca Plc, whose setbacks in drug development have made the stock the cheapest among the largest pharmaceutical companies, is turning to RNA technology to boost its chances of discovering new therapies.
By manipulating RNA, drugmakers aim either to stop cells from producing proteins that can cause diseases such as cancer and diabetes, or make needed molecules that are missing. RNA, or ribonucleic acid, helps create proteins within a cell based on genetic information encoded in DNA.